Skip to main content

Table 2 DEX-induced resistance in fresh patient-derived pancreatic tissue.

From: Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer

Time

No. of patients

Drugs

DEX1

DEX2

DEX3

Sum

24 h

18

0

11%

22%

11%

15%

  

1

44%

78%

83%

69%

  

2

44%

67%

56%

56%

  

3

56%

72%

90%

72%

48 h

20

0

10%

15%

15%

13%

  

1

60%

70%

90%

73%

  

2

50%

75%

65%

63%

  

3

60%

75%

70%

68%

72 h

18

0

56%

28%

17%

17%

  

1

44%

72%

67%

61%

  

2

39%

67%

67%

57v

  

3

56%

67%

78%

67%

Sum of drug-treated cells 1-3

  

50%

71%

74%

 

Sum of control cells 0

  

9%

22%

14%

 
  1. The percentage of cells derived from 20 patients which show statistically significant chemotherapy resistance/enhanced viability in response to treatment with dexamethasone is given. For definition of resistance, please see the Material and Methods section. Time: time point after incubation with drugs; No. of patients: indicates the number of patients whose cells were freshly isolated from resected pancreatic tissue (compare Table 2); 0: without drugs, 1: low drug concentration, 2: medium drug concentration, 3: high drug concentration of gemcitabine (25, 50 200 nM) or cisplatin (7,17,34 μM). DEX1: 0.1 μM, DEX2: 1 μM, DEX3: 10 μM.